NCT05091567 2026-03-10IMforteHoffmann-La RochePhase 3 Active not recruiting660 enrolled 23 charts 1 FDA
NCT07459634 2026-03-10A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLCJazz PharmaceuticalsPhase 2 Not yet recruiting50 enrolled